Seasonal Influenza Vaccine and Protection against Pandemic (H1N1) 2009-Associated Illness among US Military Personnel

Division of GEIS Operations, Armed Forces Health Surveillance Center, Silver Spring, Maryland, United States of America.
PLoS ONE (Impact Factor: 3.23). 05/2010; 5(5):e10722. DOI: 10.1371/journal.pone.0010722
Source: PubMed

ABSTRACT A novel A/H1N1 virus is the cause of the present influenza pandemic; vaccination is a key countermeasure, however, few data assessing prior seasonal vaccine effectiveness (VE) against the pandemic strain of H1N1 (pH1N1) virus are available.
Surveillance of influenza-related medical encounter data of active duty military service members stationed in the United States during the period of April-October 2009 with comparison of pH1N1-confirmed cases and location and date-matched controls. Crude odds ratios (OR) and VE estimates for immunized versus non-immunized were calculated as well as adjusted OR (AOR) controlling for sex, age group, and history of prior influenza vaccination. Separate stratified VE analyses by vaccine type (trivalent inactivated [TIV] or live attenuated [LAIV]), age groups and hospitalization status were also performed. For the period of April 20 to October 15, 2009, a total of 1,205 cases of pH1N1-confirmed cases were reported, 966 (80%) among males and over one-half (58%) under 25 years of age. Overall VE for service members was found to be 45% (95% CI, 33 to 55%). Immunization with prior season's TIV (VE = 44%, 95% CI, 32 to 54%) as well as LAIV (VE = 24%, 95% CI, 6 to 38%) were both found to be associated with protection. Of significance, VE against a severe disease outcome was higher (VE = 62%, 95% CI, 14 to 84%) than against milder outcomes (VE = 42%, 95% CI, 29 to 53%).
A moderate association with protection against clinically apparent, laboratory-confirmed Pandemic (H1N1) 2009-associated illness was found for immunization with either TIV or LAIV 2008-09 seasonal influenza vaccines. This association with protection was found to be especially apparent for severe disease as compared to milder outcome, as well as in the youngest and older populations. Prior vaccination with seasonal influenza vaccines in 2004-08 was also independently associated with protection.

Download full-text


Available from: Robert DeFraites, Sep 26, 2015
10 Reads
  • Source
    • "Interestingly, the last strain has been used in seasonal vaccines during the 2000/01 to 2006/07 influenza seasons. This may give place to speculation that the extent of cross-immunity induced by recent seasonal influenza vaccine is less ambiguous than originally considered [8] [9] [12] [13]. Further, these sera revealed one or more cross-neutralization epitopes that were sensitive to a conservative amino acid change in position 89 in the HA2 subunit [10], corresponding to a naturally-occurring amino acid variant that emerged in seasonal H1N1 influenza viruses in recent years [14]. "
    European geriatric medicine 01/2014; 5:136-8. · 0.73 Impact Factor
  • Source
    • "As already mentioned, previous seasonal influenza vaccination, when the circulating influenza strain was not matched by the trivalent seasonal influenza vaccine, was related to better prognosis in patients infected with influenza A(H1N1) pdm09 [21]. Moreover, prior vaccination with seasonal influenza vaccines in 2004- 2008 was independently associated with protection in a recent study [19]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study was to determine vaccination rates against influenza and pneumococcus in a large cohort of adults hospitalized with confirmed influenza A(H1N1)pdm09 infection, and to identify differences in clinical features, frequency of bacterial coinfection, and outcomes between vaccinated and non-vaccinated patients. A prospective cohort study conducted at 14 teaching hospitals in Spain. Adult patients (n=699) hospitalized with confirmed influenza A(H1N1)pdm09 infection during the pandemic and the first post pandemic influenza periods were included. Vaccination status against influenza and pneumococcus was established in 547 and 587individuals, respectively. The vaccination rates were low: 14% for seasonal influenza and 5.4% for pneumococcus. Despite conducting whole population and subgroup multivariate analyses, we observed no beneficial effects on outcomes (intensive care unit admission and mortality) for both vaccines. However, patients who had been vaccinated, whether against influenza or pneumococcus, did tend todevelop fewer bacterial coinfections, particularly that due to S. pneumoniae.
    10/2013; 1(3):22-31. DOI:10.14312/2053-1273.2013-4
  • Source
    • "A preliminary report of 32 patients with influenza A (H1N1) 2009 virus infection hospitalized in a Spanish ICU showed that pneumonia was associated with a relatively high case–fatality rate [28]. The rate of patients hospitalized in wards and the ICU with pneumonia in the 2009 pandemic was higher [3] [4] [8] [19] [29]. We sought to confirm that pneumonia was an independent risk factor for SIHC. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The objective of this paper was to develop a prognostic index for severe complications among hospitalized patients with influenza A (H1N1) 2009 virus infection. We conducted a prospective observational cohort study of 618 inpatients with 2009 H1N1 virus infection admitted to 36 Spanish hospitals between July 2009 and February 2010. Risk factors evaluated included host-related factors and clinical data at admission. We developed a composite index of severe in-hospital complications (SIHC), which included: mortality, mechanical ventilation, septic shock, acute respiratory distress syndrome, and requirement for resuscitation maneuvers. Six factors were independently associated with SIHC: age >45 years, male sex, number of comorbidities, pneumonia, dyspnea, and confusion. From the β parameter obtained in the multivariate model, a weight was assigned to each factor to compute the individual influenza risk score. The score shows an area under the receiver operating characteristic (ROC) curve of 0.77. The SIHC rate was 1.9 % in the low-risk group, 10.3 % in the intermediate-risk group, and 29.6 % in the high-risk group. The odds ratio for complications was 21.8 for the high-risk group compared with the low-risk group. This easy-to-score influenza A (H1N1) 2009 virus infection risk index accurately stratifies patients hospitalized for H1N1 virus infection into low-, intermediate-, and high-risk groups for SIHC.
    European Journal of Clinical Microbiology 04/2012; 31(10):2693-2701. DOI:10.1007/s10096-012-1616-8 · 2.67 Impact Factor
Show more